Next Phase Newsletter

A biotech sector investment firm headquartered in China opened a Boston office and raised a USD investment fund. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to help its portfolio companies reach key value-added milestones. The firm will consider opportunities based in China and North America. Companies with a strong China angle or involvement are their sweet spot.

The firm focuses mostly on therapeutics, and also open to Diagnostics. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture capital arm of a US health system looks to invest between $500K-$5M, in Seed, Series A and Series B rounds. The firm is looking to invest in technologies that can be leveraged by a large healthcare system. The group is currently looking for opportunities throughout the United States.

The girm is looking to invest in companies with strong ROI potential that also are strategically aligned with the group’s parent healthcare system. The firm is interested in companies meeting this criteria operation in the digital health, medical devices and diagnostics. The firm is open to investing in companies that are pre-revenue, including those with a product still in development or in clinical trials. The firm does not invest in therapeutics or Class III medical devices.

The firm is looking for companies with experienced management teams and generally seeks board representation following investment. The group is also interested in forming joint-ventures or co-development programs when relevant and looks to leverage its connection to the health system to aid companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporation headquartered in Tokyo, Japan with additional offices in California is interested in R&D and venture funding of new companies. Typical allocation sizes range from $0.2M-$2M, and may be structured as research funds, equity, or convertible loans depending on the phase of development. The firm will consider companies at all stages from concept to OTM, with OTM products being candidates for M&A and distribution agreements. Investments are focused on medical technology and diagnostics companies.

The firm is interested in medical technology and diagnostics companies across indications, but has a current focus in cardiovascular and regenerative indication areas.

The firm may or may not seek a board seat on companies they invest in. They are open to working with all management teams, and view deals globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company with multiple USA offices, is currently making investments from its vintage 2019 fund and is looking to make equity investments into early stage medical devices and digital health companies. The firm’s investment size varies depending on the financial needs of the company and they generally participate in seed through series B rounds. To date the firm has only made investments in companies throughout the United States though they are open to pursuing investments globally. The firm generally makes 1-2 new investment per year.

The firm is focused entirely on early stage medical devices and digital health. The firm is open to invest in all classes of medical devices and all indications and all areas of digital health. The firm generally looks to be the first round of institutional financing often investing in companies that have yet to fully develop their prototype. Companies the firm has invested in previously include devices for Orthopedics, Diagnostics, DNA Sequencing, Women’s Health, Diabetes, Imaging, and Active and Implantable Devices.

The firm is looking for companies whose market has barriers to entry, a quick path to proof of concept, and capital efficient operations. The firm looks for passionate founders and will evaluate management on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm based in Japan that is opening an office in Boston, MA, invests primarily in therapeutics, with a secondary focus in molecular diagnostics and digital health. For those fields, the firm is interested in first-in-class technology approaches and will invest in early companies with great science, from seed to series A. With their expansion to the US, the firm is now open to investing globally. The firm has generally led investments, but is willing to be part of a syndicate as well. The firmI’s investments range based on the stage of the company, but will generally be no more than $5M for seed stage and no more than $10M for series A rounds.

Within therapeutics, the firm is open to both subsector and indication as long as the science is breakthrough. The firm is willing to invest earlier in platform technology companies, and will consider such technologies as early as POC stage. For companies with single assets in development, the firm prefers to see at least small animal data. For molecular diagnostics and digital health companies, the firm is opportunistic as well.

Because the firm invests early in companies with breakthrough science, they are willing to help their portfolio companies develop their strategies and operations. With its broad and trustful network with pharma companies, the firm helps portfolio companies’ boost their businesses development activities. The firm will take a board seat after investment if needed to help the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group founded by Dr. Zhang Xu and six other Chinese medical device experts based in Suzhou, China seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel,  pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China.

The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses.

The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities.

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP.

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.